Parkinson's disease management. part iidiscovery of mao-b inhibitors based on nitrogen heterocycles and analogues

Current Topics in Medicinal Chemistry

Volumn 12, Issue 20, 2012, Pages 2116-2130

  Borges, Fernanda ^a   Reis, Joana ^a   Encarnação, Igor ^a   Gaspar, Alexandra ^a   Morales, Aliuska ^a,b   Milhazes, Nuno ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Hydrazinylthiazoles; Indoles; Isatins and phthalimides; Mao b inhibitors; Nitrogen heterocycles; Parkinson's disease and therapy; Pyridazine; Pyrimidine and pyrazole derivatives; Quinazolinones

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENSERAZIDE; BENZATROPINE; BIPERIDEN; BIPHENYL; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; COUMARIN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; HYDRAZINE; INDOLE DERIVATIVE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PROCYCLIDINE; PROFENAMINE; PYRAZOLE; RASAGILINE; SELEGILINE; THIAZOLE; TOLCAPONE; TRIHEXYPHENIDYL; XANTHONE DERIVATIVE;

ANXIETY; BLURRED VISION; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DIARRHEA; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DROWSINESS; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; HALLUCINATION; HALLUCINOSIS; HUMAN; HYPOTENSION; IC 50; INSOMNIA; LIVEDO RETICULARIS; LIVER TOXICITY; NAUSEA; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PARANOID PSYCHOSIS; PARKINSON DISEASE; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; URINE RETENTION; VOMITING; XEROSTOMIA;

EID: 84874913282     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805220020     Document Type: Review

References (101)

1. Rodriguez-Oroz, M.C.; Jahanshahi, M.; Krack, P.; Litvan, I.; Macias, R.; Bezard, E.; Obeso, J.A. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mecha nisms. Lancet Neurol., 2009, 8(12), 1128-1139.
2. Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev., 1959, 11(2, Part 2), 490-493.
3. Snyder, S.H. Virtuoso design of drugs. Nature, 1986, 323(6086), 292-293.
4. Schapira, A.H.V.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G.L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Novere, N.L.; Obeso, J.A.; Schwarzschild, M.A.; Spampinato, U.; Davidai, G., Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov., 2006, 5, (10), 845-854.
5. Schulz, J.B.; Falkenburger, B.H., Neuronal pathology in Parkin son's disease. Cell Tissue Res., 2004, 318(1), 135-147.
6. McNaught, K.S.P.; Olanow, C.W. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neuro biol. Aging, 2006, 27(4), 530-545.
7. Olanow, C.W.; Watts, R.L.; Koller, W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology, 2001, 56, (11 Suppl 5), S1-S88.
8. Nutt, J.G.; Holford, N.H.G. The response to levodopa in parkinson's disease: Imposing pharmacological law and order. Ann. Neurol., 1996, 39(5), 561-573.
9. Nagatsua, T.; Sawadab, M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat. Disord., 2009, 15 Suppl 1, S3-8.
10. Goetz, C.G.; Koller, W.C.; Poewe, W.; Rascol, O.; Sampaio, C.; Brin, M.F.; Lees, A.J.; LeWitt, P.; Lozano, A.; Mizuno, Y.; Nutt, J.; Oertel, W.; Olanow, C.W.; Tolosa, E. Management of Parkinson's Disease: An Evidence-Based Review: Levodopa. Movement Disord., 2002, 17(S4), S23-S37.
11. Barbeau, A.; Mars, H.; Botez, M.I.; Joubert, M. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease. Can. Med. Assoc. J., 1972, 106(11), 1169-1174.
12. Olanow, C.W. Attempts to obtain neuroprotection in Parkinson's disease. Neurology, 1997, 49, (1 Suppl 1), S26-33.
13. Weintraub, D. Dopamine and impulse control disorders in Parkinson's disease. Ann. Neurol., 2008, 64(S2), S93-S100.
14. Goetz, C.G.; Koller, W.C.; Poewe, W.; Rascol, O.; Sampaio, C.; Brin, M.F.; Lees, A.J.; LeWitt, P.; Lozano, A.; Mizuno, Y.; Nutt, J.; Oertel, W.; Olanow, C.W.; Tolosa, E. Management of Parkinson's Disease: An Evidence-Based Review: DA agonists Overview. Movement Disord., 2002, 17(S4), S52-S52.
15. Schapira, A.H.V.; Olanow, C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann. Neurol., 2008, 64(S2), S47-S55.
16. Rezak, M. Current pharmacotherapeutic treatment options in Parkinson's Disease. Disease-a-Month, 2007, 53(4), 214-222.
17. Kincses, Z.T.; Vecsei, L. Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection. CNS Neurosci. Ther., 2011, 17(5), 345-367.
18. Schapira, A.H.; Olanow, C.W. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann. Neurol., 2003, 53 Suppl 3, S149-S157.
19. Yoshioka, M.; Tanaka, K.I.; Miyazaki, I.; Fujita, N.; Higashi, Y.; Asanuma, M.; Ogawa, N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res., 2002, 43(3), 259-267.
20. Ogawa, N.; Tanaka, K.I.; Asanuma, M.; Kawai, M.; Masumizu, T.; Kohno, M.; Mori, A., Bromocriptine protects mice against 6hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res., 1994, 657(1-2), 207-213.
21. Schapira, A.H.V. Future directions in the treatment of Parkinson's disease. Movement Disord., 2007, 22(S17), S385-S391.
22. Singh, N.; Pillay, V.; Choonara, Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol., 2007, 81(1), 29-44.
23. Syvalahti, E.K.; Kunelius, R.; Lauren, L. Effects of antiparkin sonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol. Toxicol., 1988, 62(2), 90-94.
24. LeWitt, P.A.; Ward, C.D.; Larsen, T.A.; Raphaelson, M.I.; Newman, R.P.; Foster, N.; Dambrosia, J.M.; Calne, D.B. Compa rison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 1983, 33(8), 1009-1014.
25. Lees, A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging, 2005, 22(9), 731-740.
26. Olanow, C.W.; Schapira, A.H.V.; Agid, Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol., 2003, 53(Suppl 3), S1-2.
27. D.R. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharm. Sci., 1999, 2(2), 39-46.
28. Robert S. Schwab, M.; Albert C. England Jr., M.; David C. Poskanzer, M.; Robert R. Young, M. Amantadine in the Treatment of Parkinson's Disease. JAMA, 1969, 208(7), 1168-1170.
29. Calne, D.B. Treatment of Parkinson's disease. N. Engl. J. Med., 1993, 329(14), 1021-1027.
30. Adler, C.H.; Stern, M.B.; Vernon, G.; Hurtig, H.I. Amantadine in advanced Parkinson's disease: good use of an old drug. J. Neurol., 1997, 244(5), 336-337.
31. Shannon, K.M.; Goetz, C.G.; Carroll, V.S.; Tanner, C.M.; Klawans, H.L. Amantadine and Motor Fluctuations in Chronic Parkinson's Disease. Clin. Neuropharmacol., 1987, 10(6), 522-526.
32. Goetz, C.G.; Koller, W.C.; Poewe, W.; Rascol, O.; Sampaio, C.; Brin, M.F.; Lees, A.J.; LeWitt, P.; Lozano, A.; Mizuno, Y.; Nutt, J.; Oertel, W.; Olanow, C.W.; Tolosa, E., Amantadine and other antiglutamate agents. Movement Disord., 2002, 17, (Suppl 4), S13-S22.
33. Gordin, A.; Kaakkola, S.; Teravainen, H. Clinical advantages of COMT inhibition with entacapone a review. J. Neural. Transm., 2004, 111(10-11), 1343-1363.
34. Burguera, J.A. Entacapone: is it useful as complimentary treatment with levodopa?. Rev Neurologia, 1999, 28(8), 817-834.
35. Fénelon, G.; Giménez-Roldán, S.; Montastruc, J.L.; Bermejo, F.; Durif, F.; Bourdeix, I.; Péré, J.J.; Galiano, L.; Schadrack, J. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J. Neural. Transmission, 2003, 110(3), 239-251.
36. Olanow, C.W. Tolcapone and Hepatotoxic Effects. Arch. Neurol, 2000, 57(2), 263-267.
37. Johnston, J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol, 1968, 17(7), 1285-1297.
38. Gaspar, A.; Silva, T.; Yáñez, M.; Vina, D.; Orallo, F.; Ortuso, F.; Uriarte, E.; Alcaro, S.; Borges, F., Chromone, A. Privileged Scaffold for the Development of Monoamine Oxidase Inhibitors. J. Med. Chem., 2011, 54(14), 5165-5173.
39. Foley, P.; Gerlach, M.; Youdim, M.B.; Riederer, P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat. Disord., 2000, 6(1), 25-47.
40. Goetz, C.G.; Koller, W.C.; Poewe, W.; Rascol, O.; Sampaio, C; Brin, M.F.; Lees, A.J.; LeWitt, P.; Lozano, A.; Mizuno, Y.; Nutt, J.; Oertel, W.; Olanow, C.W.; Tolosa, E., Management of Parkinson's Disease: An Evidence-Based Review: MAO-B inhibitors for the treatment of Parkinson's disease. Movement Disord., 2002, 17(S4), S38-S44.
41. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7(4), 295-309.
42. Youdim, M.B.; Bakhle, Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol, 2006, 147 Suppl 1, S287-296.
43. Takahata, K.; Shimazu, S.; Katsuki, H.; Yoneda, F.; Akaike, A., Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural. Transm., 2006, 113(2), 151-158.
44. F. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging, 1999, 14(5), 337-345.
45. Birks, J.; Flicker, L. Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev., 2003, (1), CD000442.
46. Kennedy, B.P.; Ziegler, M.G.; Alford, M.; Hansen, L.A.; Thal, L.J.; Masliah, E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J. Neural. Transm., 2003, 110(7), 789-801.
47. Rascol, O.; Brooks, D.J.; Melamed, E.; Oertel, W.; Poewe, W.; Stocchi, F.; Tolosa, E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 2005, 365, (9463), 947-954.
48. Youdim, M.B.; Maruyama, W.; Naoi, M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today, 2005, 41(6), 369-391.
49. Andricopulo, A.D.; Montanari, C.A. Structure-activity relation ships for the design of small-molecule inhibitors. Mini Rev. Med. Chem., 2005, 5(6), 585-593.
50. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V.; Mondovì, B.; Cirilli, R.; La Torre, F., Synthesis and selective inhibitory activity of 1-acetyl3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against mono amine oxidase. J. Med. Chem., 2004, 47(8), 2071-2074.
51. Pisani, L.; Muncipinto, G.; Miscioscia, T.; Nicolott, i.O.; Leonetti, F.; Catto, M.; Caccia, C; Salvati, P.; Soto-Otero, R.; MendezAlvarez, E.; Passeleu, C; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J. Med. Chem., 2009, 52(21). 6685-6706.
52. Matos, M.J.; Vina, D.; Picciau, C; Orallo, F.; Santana, L.; Uriarte, E., Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett, 2009, 19(17), 5053-5055.
53. Matos, M.J.; Viña, D.; Quezada, E.; Picciau, C; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E., A new series of 3-phenyl coumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett, 2009, 19(12), 3268-3270.
54. Gökhan-Kelekçi, N.; Simsek, O.; Ercan, A; Yelekçi, K.; Sahin, Z.; Isik, S.; Uçar, G.; Bilgin, A. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Bioorg. Med. Chem., 2009, 17(18), 6761-6772.
55. Prins, L.H.; Petzer, J.P.; Malan, S.F., Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur. J. Med. Chem., 2010, 45(10), 4458-4466.
56. Gaspar, A.; Reis, J.; Fonseca, A.; Milhazes, N.; Viña, D.; Uriarte, E.; Borges, F., Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(2), 707-709.
57. Alcaro, S.; Gaspar, A.; Ortuso, F.; Milhazes, N.; Orallo, F.; Uriarte, E.; Yáñez, M.; Borges, F., Chromone-2and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg. Med. Chem. Lett., 2010, 20(9), 2709-2712.
58. Helguera, A.M.; Perez-Machado, G.; Cordeiro, M.N.; Borges, F. Discovery of MAO-B inhibitors present status and future directions. Part I: Oxygen heterocycles and analogues. Mini-Rev. Med. Chem., 2012, [Epub ahead of print].
59. Song, B.; Xiao, T.; Qi, X.; Li, L.N.; Qin, K.; Nian, S.; Hu, G.X.; Yu, Y.; Liang, G.; Ye, F., Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(4), 1739-1742.
60. Booysen, H.P.; Moraal, C.; Terre'Blanche, G.; Petzer, A.; Bergh, J.J.; Petzer, J.P., Thioand aminocaffeine analogues as inhibitors of human monoamine oxidase. Bioorg. Med. Chem., 2011, 19(24), 7507-7518.
61. Carroll, R.T.; Dluzen, D.E.; Stinnett, H.; Awale, P.S.; Funk, M.O.; Geldenhuys, W.J., Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B. Bioorg. Med. Chem. Lett., 2011, 21(16), 4798-4803.
62. Altomare, C.; Cellamare, S.; Summo, L.; Catto, M.; Carotti, A. Inhibition of Monoamine Oxidase-B by Condensed Pyridazines and Pyrimidines: Effects of Lipophilicity and Structure-Activity Relationships. J. Med. Chem., 1998, 41, 3812-3820.
63. Carrieri, A.; Carotti, A.; Barreca, M.L.; Altomare, C., Binding models of reversible inhibitors to type-B monoamine oxidase. J. Computer-Aided Mol. Des., 2002, 16, 769-778.
64. Jayaprakash, V.; Sinha, B.N.; Ucar, G.; Ercan, A., Pyrazolinebased mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(24), 6362-6368.
65. Gokhan-Kelekci, N.; Koyunoglu, S.; Yabanoglu, S.; Yelekci, K.; Ozgen, O.; Ucar, G.; Erol, K.; Kendi, E.; Yesilada, A. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural deter minants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem., 2009, 17, (2), 675-689.
66. Gokhan-Kelekci, N.; Yabanoglu, S.; Kupeli, E.; Salgin, U.; Ozgen, O.; Ucar, G.; Yesilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A., A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and anti inflammatory analgesics. Bioorg. Med. Chem., 2007, 15(17), 5775-5786.
67. Mishra, N.; Sasmal, D., Development of selective and reversible pyrazoline based MAO-B inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21(7), 1969-1973.
68. Sahoo, A.; Yabanoglu, S.; Sinha, B.N.; Ucar, G.; Basu, A.; Jayaprakash, V. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2010, 20(1), 132-136.
69. Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yanez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D., Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur. J. Med. Chem., 2010, 45(10), 4490-4498.
70. Fioravanti, R.; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yanez, M.; Vitali, A.; Ortuso, F.; Alcaro, S., Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(22), 6479-6482.
71. Jagrat, M.; Behera, J.; Yabanoglu, S.; Ercan, A.; Ucar, G.; Sinha, B.N.; Sankaran, V.; Basu, A.; Jayaprakash, V., Pyrazoline based MAO inhibitors: Synthesis, biological evaluation and SAR studies. Bioorg. Med. Chem. Lett., 2011, 21(14), 4296-4300.
72. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre, F.; Cardia, M.C.; Distinto, S. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro (1H)pyrazole derivatives. J. Med. Chem., 2005, 48(23), 7113-7122.
73. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cardia, M.C.; Distinto, S., Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives. J. Med. Chem., 2007, 50(4), 707-712.
74. Yabanoglu, S.; Ucar, G.; Gokhan, N.; Salgin, U.; Yesilada, A.; Bilgin, A. A. Interaction of rat lung SSAO with the novel 1-Nsubstituted thiocarbamoyl-3-substituted phenyl-5-(2-pyrolyl)-2pyrazoline derivatives. J. Neural. Transm., 2007, 114(6), 769-773.
75. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T., Synthesis, biological evaluation and 3DQSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole deriva tives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem., 2006, 13(12), 1411-1428.
76. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yanez, M.; Orallo, F., Synthesis and inhibitory activity against human monoamine oxidase of N1thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2010, 45(2), 800-804.
77. Chimenti, F.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S., Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors. Bioorg. Med. Chem., 2010, 18(15), 5715-5723.
78. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F., Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg. Med. Chem. Lett., 2004, 14(14), 3697-3703.
79. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N'-bis[2-oxo-2Hbenzopyran]-3-carboxamides. Bioorg. Med. Chem. Lett., 2006, 16(15), 4135-4140.
80. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S., Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7substituted coumarins. J. Med. Chem., 2009, 52(7), 1935-1942.
81. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Alcaro, S.; Ortuso, F.; Yanez, M.; Orallo, F.; Cirilli, R.; Ferretti, R.; La Torre, F., Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene(4-arylthiazol-2-yl)hydrazones. J. Med. Chem., 2008, 51(16), 4874-4880.
82. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Maccioni, E.; Cardia, M.C.; Yanez, M.; Orallo, F.; Alcaro, S.; Ortuso, F.; Cirilli, R.; Ferretti, R.; Distinto, S.; Kirchmair, J.; Langer, T., Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg. Med. Chem., 2010, 18(14), 5063-5070.
83. Tipton, K.F., Inhibition of monoamine oxidase by substituted hydrazines. Biochem. J., 1972, 128(4), 913-919.
84. Dar, A.; Khan, K.M.; Ateeq, H.S.; Khan, S.; Rahat, S.; Perveen, S.; Supuran, C.T., Inhibition of monoamine oxidase-A activity in rat brain by synthetic hydrazines: structure-activity relationship (SAR). J. Enzyme Inhib. Med. Chem., 2005, 20(3), 269-274.
85. Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry, 2008, 47(20), 5616-5625.
86. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; D'Ascenzio, M.; Yanez, M.; Orallo, F., Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones. Med. Chem. Comm., 2010, 1(1), 61-72.
87. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Bizzarri, B. Synthesis and Biological Evaluation of Novel Conjugated Coumarin-Thiazole Systems. J. Heterocyclic. Chem., 2009, 46(3), 575-578.
88. Shaharyar, M.; Siddiqui, A.A.; Ali, M.A. Synthesis and evaluation of phenoxy acetic acid derivatives as anti-mycobacterial agents. Bioorg. Med. Chem. Lett., 2006, 16(17), 4571-4574.
89. Balsa, D.; Fernandez-Alvarez, E.; Tipton, K.F.; Unzeta, M. Inhibition of MAO by substituted tryptamine analogues. J. Neural. Transm. Suppl., 1990, 32, 103-105.
90. Balsa, D.; Fernandez-Alverez, E.; Tipton, K.F.; Unzeta, M., Monoamine oxidase inhibitory potencies and selectivities of 2-[N(2-propynyl)-aminomethyl]-1-methyl indole derivatives. Biochem. Soc. Trans., 1991, 19(1), 215-218.
91. Fernández García, C.; Marco, J.L.; Fernández-Alvarez, E., Acetylenic and allenic derivatives of 2-(5-methoxy-1-methylin dolyl) alkylamines: Synthesis and evaluation as selective inhibitors of the monoamine oxidases A and B. Eur. J. Med. Chem., 1992, 27(9), 909-918.
92. Moron, J.A.; Campillo, M.; Perez, V.; Unzeta, M.; Pardo, L. Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: biological activities, 3D-QSAR/ CoMFA analysis, and computational simulation of ligand recognition. J. Med. Chem., 2000, 43(9), 1684-1691.
93. Perez, V.; Marco, J.L.; Fernandez-Alvarez, E.; Unzeta, M., Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol., 1999, 127(4), 869-876.
94. Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E., Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005, 280(16), 15761-15766.
95. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A., Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U S A., 2005, 102(36), 12684-12689.
96. Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; Castagnoli Jr, N.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg. Med. Chem. Lett., 2009, 19(9), 2509-2513.
97. Manley-King, C.I.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by C5-substituted phthalimide analogues. Bioorg. Med. Chem., 2011, 19(16), 4829-4840.
98. Manley-King, C.I.; Bergh, J.J.; Petzer, J.P., Inhibition of monoamine oxidase by selected C5and C6-substituted isatin analogues. Bioorg. Med. Chem., 2011, 19(1), 261-274.
99. Manley-King, C.I.; Bergh., J.J.; Petzer, J.P. Inhibition of monoamine oxidase by selected C5and C6-substituted isatin analogues. Russ. J. Org. Chem., 2006, 42, 261-274.
100. Strydom, B.; Malan, S.F.; Castagnoli Jr, N.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg. Med. Chem., 2010, 18(3), 1018-1028.
101. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P. A.; Reist, M., Impact of speciesdependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49, 6264-6272.